Related Experiment Video
Updated: May 23, 2026

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
Published on: May 8, 2016
miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients
Julio Cesar Cetrulo Lorenzi1, Doralina G Brum, Dalila L Zanette
1Genetics Department, São Paulo University Medical school of Ribeirão Preto, Ribeirão Preto, Brazil.
Abstract:
The pathology of relapsing-remitting multiple sclerosis (RR-MS) is largely attributed to activated autoreactive effector T lymphocytes. The influence of microRNAs on the immune response has been shown to occur in different pathways of lymphocyte differentiation and function. Here, the expression of the miRNAs miR-15a/16-1 in PBMC, CD4(+), and CD8(+) from RR-MS patients has been investigated. BCL2, a known miR-15a/16-1 target, has also been analyzed. The results have shown that miR-15a/16-1 is downregulated in CD4(+) T cells, whereas BCL2 is highly expressed in RR-MS patients only. Our data suggest that miR-15a/16-1 can also modulate the BCL2 gene expression in CD4(+) T cells from RR-MS patients, thereby affecting apoptosis processes.
Insights
MicroRNAs, specifically miR-15a/16-1, are downregulated in CD4(+) T cells of relapsing-remitting multiple sclerosis (RR-MS) patients. This impacts BCL2 expression and may affect T cell apoptosis in RR-MS.
Area of Science:
- Immunology
- Molecular Biology
- Neuroscience
Background:
- Relapsing-remitting multiple sclerosis (RR-MS) pathology involves activated autoreactive T lymphocytes.
- MicroRNAs play a role in regulating lymphocyte differentiation and function.
- Understanding molecular mechanisms in RR-MS is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the expression of miR-15a/16-1 in peripheral blood mononuclear cells (PBMC), CD4(+), and CD8(+) T cells from RR-MS patients.
- To analyze the expression of BCL2, a known target of miR-15a/16-1, in RR-MS patients.
- To explore the potential role of miR-15a/16-1 in modulating BCL2 gene expression and apoptosis in CD4(+) T cells from RR-MS patients.
Main Methods:
- Quantification of miR-15a/16-1 expression in PBMC, CD4(+), and CD8(+) T cells.
- Analysis of BCL2 gene expression.
- Comparison of miRNA and BCL2 levels between RR-MS patients and controls (implied).
Main Results:
- miR-15a/16-1 was found to be downregulated in CD4(+) T cells of RR-MS patients.
- BCL2 expression was significantly higher in RR-MS patients.
- Data suggest miR-15a/16-1 modulates BCL2 expression in CD4(+) T cells, influencing apoptosis.
Conclusions:
- Downregulation of miR-15a/16-1 in CD4(+) T cells is a feature of RR-MS.
- The observed changes in miR-15a/16-1 and BCL2 expression may contribute to the aberrant T cell function and apoptosis seen in RR-MS.
- These findings highlight a potential therapeutic target for modulating T cell responses in RR-MS.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Multiple Sclerosis l: Introduction
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
